Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Operating Expenses (2020 - 2022)

Historic Operating Expenses for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to $39.9 million.

  • Atea Pharmaceuticals' Operating Expenses fell 4380.34% to $39.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $130.6 million, marking a year-over-year decrease of 3865.94%. This contributed to the annual value of $193.0 million for FY2024, which is 1753.63% up from last year.
  • As of Q4 2022, Atea Pharmaceuticals' Operating Expenses stood at $39.9 million, which was down 4380.34% from $16.3 million recorded in Q3 2022.
  • Atea Pharmaceuticals' Operating Expenses' 5-year high stood at $71.0 million during Q4 2021, with a 5-year trough of $10.0 million in Q2 2020.
  • In the last 3 years, Atea Pharmaceuticals' Operating Expenses had a median value of $35.3 million in 2021 and averaged $36.3 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 41688.49% in 2021, then crashed by 7037.56% in 2022.
  • Quarter analysis of 3 years shows Atea Pharmaceuticals' Operating Expenses stood at $28.0 million in 2020, then soared by 153.69% to $71.0 million in 2021, then crashed by 43.8% to $39.9 million in 2022.
  • Its Operating Expenses stands at $39.9 million for Q4 2022, versus $16.3 million for Q3 2022 and $32.3 million for Q2 2022.